[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100568963":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":23,"responsibleParty":41,"collaborators":43,"id":45,"slug":7,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":7,"eligibilityCriteria":49,"healthyVolunteers":46,"sex":50,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":56,"studyType":57,"phases":7,"briefSummary":58,"conditions":59,"keywords":64,"overallStatus":26,"whyStopped":7,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Tianjin Medical University","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DIAGNOSTIC_TEST","Single Group Assignment","68Ga-DOTA\u002FNOTA-FAPI-04 Each subject receive a single intravenous injection of 68Ga\u002F18F-FAPI, and undergo PET\u002FCT imaging within the specificed time.",[14,19],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Haonan Yu, MD","CONTACT","+8613821000597","dreamadam@126.com",{"name":20,"role":16,"phone":21,"phoneExt":7,"email":22},"Shaobo Yao, PhD","+8615122570279","yaoshaobo008@163.com",[24],{"facility":25,"status":26,"city":27,"state":28,"zip":29,"country":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"Tianjin Medical University General Hospital","RECRUITING","Tianjin","Tianjin Municipality","300052","China",{"type":32,"coordinates":33},"Point",[34,35],117.17667,39.14222,{"lat":35,"lon":34},[38,39],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},{"name":20,"role":40,"phone":7,"phoneExt":7,"email":7},"PRINCIPAL_INVESTIGATOR",{"type":40,"investigatorFullName":20,"investigatorTitle":42,"investigatorAffiliation":25,"oldNameTitle":7,"oldOrganization":7},"Prof.",[44],{"name":25,"class":6},"100568963",false,"NCT06688071","FAPI PET\u002FCT in Various FAP-Related Disease Patients","Inclusion Criteria:\n\n* (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled FAPI PET\u002FCT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n* (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.","ALL","18 Years","80 Years",{"count":54,"type":55},500,"ESTIMATED","7 Days","OBSERVATIONAL","To evaluate the potential usefulness of 68Ga\u002F18F-FAPI positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the diagnosis of primary and metastatic lesions in various FAP-related disease patients.",[60,61,62,63],"FAP-related Disease","Tumor","Positron Emission Tomography","Metastasis",[65,66,67],"PET\u002FCT","FAP","FAPI","2025-02-07",{"date":70,"type":71},"2025-02-11","ACTUAL",{"date":73,"type":71},"2022-03-01",{"date":75,"type":55},"2027-10-01",{"name":5,"class":6},1]